UCART20x22 Receives FDA IND Clearance; Novel Universal CAR-T Program; No Clinical Milestone Updates for UCART22, UCART123, or UCARTCS1; Cellectis’s Q2 2022 Earnings Call Summary
On Friday, August 5, Cellectis held their Q2 2022 earnings call (press release) highlighting UCART20x22’s (allogeneic CD20xCD22 dual CAR-T) FDA IND clearance for r/r NHL. Of note, no major clinical updates were provided for allogeneic therapies UCART22 (CD22 CAR-T), UCART123 (CD123 CAR-T) or UCARTCS1 (CS1 CAR-T). Below, Celltelligence provides insights on Cellectis’s FDA IND clearance and pipeline development.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.